[18F]Fluciclovine PET discrimination between high- and low-grade gliomas

EJNMMI Research

Table 1 Patient demographics

Lesion	Patient sex	Age	Histopathology	WHO grade	Histologic verification (days before PET)	Ki-67 (%)
1	F	58	Oligodendroglioma	II	SB (4 day)	3
2	M	38	Oligodendroglioma	II	SB (19 day)	3
3	M	56	Diffuse astrocytoma	II	SB (13 day)	4
4	M	36	Oligodendroglioma	II	SB (14 day)	< 1
5	M	39	Oligodendroglioma	II	EB (42 day)	N/A
6	F	32	Diffuse astrocytoma	II	EB (61 day)	4
7	M	45	Anaplastic astrocytoma	III	EB (31 day)	40
8	F	50	Glioblastoma	IV	SB (7 day)	12
9	M	70	Glioblastoma	IV	SB (15 day)	40
10^a	F	72	Glioblastoma	IV	SB (27 day)	30
11^a	F	72	Glioblastoma	IV	SB (27 day)	30
12	M	58	Glioblastoma	IV	EB (3 day)	N/A
13^a	F	36	Glioblastoma	IV	EB (13 day)	N/A
14^a	F	36	Glioblastoma	IV	EB (13 day)	N/A
15	F	58	Glioblastoma	IV	EB (14 day)	10
16	F	65	Glioblastoma	IV	EB (16 day)	35
17	M	67	Glioblastoma	IV	EB (13 day)	8
18	F	60	Glioblastoma	IV	EB (18 day)	N/A

SB stereotactic biopsy, EB excisional biopsy/partial resection, N/A not available
^aIndicates lesions from the same patient